1. Home
  2. EXPD vs BIIB Comparison

EXPD vs BIIB Comparison

Compare EXPD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXPD
  • BIIB
  • Stock Information
  • Founded
  • EXPD 1979
  • BIIB 1978
  • Country
  • EXPD United States
  • BIIB United States
  • Employees
  • EXPD N/A
  • BIIB N/A
  • Industry
  • EXPD Oil Refining/Marketing
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXPD Consumer Discretionary
  • BIIB Health Care
  • Exchange
  • EXPD Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • EXPD 16.3B
  • BIIB 24.2B
  • IPO Year
  • EXPD N/A
  • BIIB 1991
  • Fundamental
  • Price
  • EXPD $139.64
  • BIIB $166.54
  • Analyst Decision
  • EXPD Hold
  • BIIB Buy
  • Analyst Count
  • EXPD 10
  • BIIB 24
  • Target Price
  • EXPD $129.22
  • BIIB $174.62
  • AVG Volume (30 Days)
  • EXPD 1.6M
  • BIIB 1.8M
  • Earning Date
  • EXPD 11-04-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • EXPD 1.08%
  • BIIB N/A
  • EPS Growth
  • EXPD 20.10
  • BIIB N/A
  • EPS
  • EXPD 6.15
  • BIIB 10.97
  • Revenue
  • EXPD $11,167,760,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • EXPD $3.06
  • BIIB $2.97
  • Revenue Next Year
  • EXPD N/A
  • BIIB N/A
  • P/E Ratio
  • EXPD $23.13
  • BIIB $15.01
  • Revenue Growth
  • EXPD 12.54
  • BIIB 4.77
  • 52 Week Low
  • EXPD $100.47
  • BIIB $110.04
  • 52 Week High
  • EXPD $142.75
  • BIIB $169.00
  • Technical
  • Relative Strength Index (RSI)
  • EXPD 66.63
  • BIIB 70.28
  • Support Level
  • EXPD $137.30
  • BIIB $151.83
  • Resistance Level
  • EXPD $142.09
  • BIIB $169.00
  • Average True Range (ATR)
  • EXPD 4.05
  • BIIB 5.90
  • MACD
  • EXPD 0.95
  • BIIB 1.22
  • Stochastic Oscillator
  • EXPD 87.15
  • BIIB 93.71

About EXPD Expeditors International of Washington Inc.

Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: